Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.
A user shared their experience with DIY PRP scalp injections for hair regrowth, using an EZ Injector and other at-home equipment. Another user reported success with at-home PRP treatments for 1.5 years, noting thicker hair and a stable hairline.
A user's regimen to help with their diffuse thinning, which includes taking Pyrilutamide BID, 1mg finasteride daily, 2.5mg oral minoxidil daily, topical minoxidil since August 2021, LLLT every two days, topical fin, progesterone, melatonin, minoxidil (started one week ago), pumpkin seed oil and not dermarolling; other commenters suggested Nizoral for dandruff control and caution when using pre-mixed products with Pyrilutamide.
The conversation discusses the use of Finastopic, a carrier for finasteride solutions by Isdin, and compares it to a standard propylene glycol (PG) solution. The user was prescribed a 1% finasteride solution using Finastopic and has been using a self-compounded 0.025% topical finasteride with minoxidil.
Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.
The user is considering buzzing their long hair to better assess the effects of finasteride, which they have been using for over two months, and is concerned about maintaining their unique appearance. They are also curious if dyeing short hair could cause any issues.
User discusses using C60 serum with microneedling at 1.75mm and asks if it's safe. Current routine includes daily Pyril on temples, weekly microneedling, and C60 serum on non-Pyril days.
The user has been using topical minoxidil for over a year and added kx826/pyrilutamide to improve hair growth, avoiding finasteride due to side effects like lowered libido and panic attacks. They report positive results with reduced shedding and healthier hair, particularly in areas previously unresponsive to minoxidil.
Petal Fresh Hair ResQ shampoo is discussed for hair loss, with skepticism about its effectiveness. Minoxidil is mentioned as part of a treatment plan, and other recommended ingredients include Piroctone Olamine, Ketoconazole, and Saw Palmetto.
The user is currently using finasteride and minoxidil and is considering adding microneedling and either RU58841 or Pyrilutamide for potential hair regrowth. They previously used microneedling, RU58841, and oral minoxidil before their hair transplant.
A user with diffuse hair loss for a decade tried various treatments, including LLLT Helmet, supplements, topicals, and hair transplants. They found relief from scalp inflammation and itching using a topical solution made from crushed Xeljanz pills mixed with ethyl alcohol.
Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.
The conversation is about when the phase 3 results for pyrilutamide, a potential hair loss treatment, will be released. There was a letter about the study a month ago, but the actual results were not included.
Pyrilutamide's 0.5% solution showed minimal improvement, while the 1% solution appears more promising but costly. The user is currently using finasteride and oral minoxidil and considering adding Pyrilutamide if effective and affordable.
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.
PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.
The user shared their hair regrowth progress using a combination of treatments including finasteride, dutasteride, minoxidil, tretinoin, Sulfogenz, KX-826, low-level laser therapy, and microneedling. They plan to continue medication for another year before considering a hair transplant, noting steady improvement but not major changes.
OP experienced diffuse thinning for 11 years and used Minoxidil and Finasteride previously. They now use Pyrilutamide 0.5% and Alfatradiol 0.1%, resulting in significantly reduced hair loss.
A new hair loss treatment, pp405, may regrow hair better than finasteride and minoxidil, with potential availability by 2028. However, there is skepticism about its effectiveness and commercialization timeline.
Kintor is producing a cosmetic with KX826, starting at 0.5% concentration and moving to 1%. The 0.5% concentration wasn't as effective as minoxidil and finasteride, but the 1% concentration shows promise.
Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.
People are discussing the use of an untested hair loss treatment called PP405, which is not available on the grey market. Some users are trying a mimic formulation called HP3, reporting thicker hair but no new growth yet.
Pyrilutamide is being discussed as an alternative for those who can't use finasteride, but users report it may be ineffective at low concentrations. Some users are combining it with minoxidil, microneedling, and other treatments, but results vary.
The conversation is about the stability of pyrilutamide in different solutions. The user is asking if a 70/30 ethanol/pg solution with 4% water will degrade pyrilutamide.
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
The conversation discusses the effectiveness of pyrithione zinc and GT20029 for hair loss. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.